3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
52
Phase 1
20
Phase NA
16
Phase 1/2
6
Phase 3
4
Phase 2/3
2
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
9
Thoracic
2
Gastrointestinal
2
Endocrine
2
Lymphoid
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Neuroendocrine Tumors
7
Thyroid Carcinoma, Anaplastic
3
Thyroid Cancer, Papillary
3
Neoplasms
3
Multiple Endocrine Neoplasia Type 1
3
Thyroid Neoplasms
2
Somatostatinoma
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Laryngeal Neoplasms
2
Hematologic Neoplasms
2
Glioma
2
Gastroenteropancreatic Neuroendocrine Tumors
2
Erdheim-Chester Disease
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Adrenal Gland Neoplasms
2
Adenoma, Islet Cell
2
Vipoma
1
Thyroid cancer, Hurthle cell
1
Pituitary Neoplasms
1
Pheochromocytoma
1
Parathyroid Neoplasms
1
Paraganglioma
1
Muscle Weakness
1
Motor Activity
1
Melanoma
1
Interventions
fosbretabulin
1
combretastatin
1
Sodium Iodide
1
Paclitaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Thyroid Neoplasms
×
Endocrine
×
Clear all
NCT01398085
2026-05-07
IoN
University College, London
Phase 2/3
Active not recruiting
504 enrolled
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts